Clinical disorders of fibrinolysis: a critical review.
Much progress has recently been made in understanding the biochemistry and physiology of endogenous fibrinolysis. As a result, a better understanding of the mechanisms and clinical consequences of disordered fibrinolysis has emerged. Increased fibrinolytic activity is an uncommon but important cause of hemorrhagic disease. Congenital disorders of fibrinolysis which cause bleeding include increased plasma plasminogen activator activity and deficiency of alpha-2 antiplasmin. Acquired disorders associated with increased fibrinolytic activity and bleeding include liver cirrhosis, amyloidosis, acute promyelocytic leukemia, some solid tumors, and certain snake envenomation syndromes. Increased fibrinolysis is important to recognize because epsilon-aminocaproic acid (EACA) may be required to prevent or control bleeding. Diminished fibrinolytic activity has been associated with a variety of thrombotic disorders, but a direct cause-and-effect relationship has yet to be established. Congenital abnormalities of fibrinolysis associated with thrombosis include plasminogen deficiency, decreased endothelial generation of plasminogen activator activity, and certain abnormal fibrinogens. Thrombosis in these disorders is effectively managed with warfarin. Diminished fibrinolysis has also been reported in "idiopathic" venous thrombosis, oral contraceptive-induced and post-operative venous thrombosis, coronary artery disease, cerebrovascular disease, systemic lupus erythematosus, and thrombotic thrombocytopenic purpura, but the significance of abnormal fibrinolysis in these disorders is uncertain. Large, prospective studies of fibrinolytic variables as risk factors for vascular and thrombotic disease are needed to determine whether pharmacologic augmentation of impaired fibrinolysis could be useful in the prevention or treatment of these disorders.
Francis
R B
RB
Department of Medicine, University of Southern California School of Medicine, Los Angeles.
D001778:Blood Coagulation Disorders / Q000503:physiopathology*; D005260:Female; D005341:Fibrinolysin / Q000502:physiology*; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors / Q000502:physiology; D015849:Plasminogen Inactivators; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic; D013927:Thrombosis / Q000503:physiopathology*
D015849:Plasminogen Inactivators; D010960:Plasminogen Activators; D005341:Fibrinolysin